Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

We recently published a list of 15 Best Dividend Stocks To Buy and Hold. In this article, we are going to take a look at ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...